Complex Lymphatic Anomaly (CLA) is an umbrella term encompassing four overlapping but distinct rare diseases of the lymphatic system; Gorham Stout Disease (GSD); Generalized Lymphatic Anomaly (GLA); Kaposiform Lymphangiomatosis (KLA); and Central Conducting Lymphatic Anomaly (CCLA). CLAs are characterized by growth of abnormal lymphatic tissue involving both soft tissue and bone leading to chronic and debilitating conditions that can be fatal.
The LMI was established in 2010 to support research that drives our understanding of the pathobiology and genetics of CLAs. The institute also supports and funds clinical and translational research to better define the impact of CLAs on our patients, testing of new therapies and finding biomarkers of disease activity and treatment response. LMI fosters an interactive and collaborative research community inclusive of patients and research and medical professionals, where our research drives improved quality of life and ultimately cures for patients with CLAs.